All In Biotech

Drug Trial Radar · NCT07717879

Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

A Phase 3, Randomized, 6-Week, Double-blind, Placebo-controlled Trial of Solriamfetol in Children Aged 6 to <12 Years With Attention Deficit Hyperactivity Disorder (ADHD)

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 468 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

468

Planned (sponsor's estimate)

Start

Jul 6, 2026

Primary completion

Jun 30, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Axsome Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in children aged 6 to \<12 years with ADHD.

Conditions

  • ADHD

Interventions

  • Solriamfetol Dose ADrug

    Solriamfetol capsules, taken once daily

  • Solriamfetol Dose BDrug

    Solriamfetol capsules, taken once daily

  • PlaceboDrug

    Placebo capsules, taken once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ADHD-RS-5 Total Score, Change from Baseline to Week 6Time frame: 6 weeks

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Site

    Dothan, Alabama · Recruiting

  • Clinical Research Site

    Little Rock, Arkansas · Recruiting

  • Clinical Research Site

    Anaheim, California · Recruiting

  • Clinical Research Site

    Irvine, California · Recruiting

  • Clinical Research Site

    Long Beach, California · Recruiting

  • Clinical Research Site

    Orange, California · Recruiting

  • Clinical Research Site

    Walnut Creek, California · Recruiting

  • Clinical Research Site

    Coral Gables, Florida · Recruiting

  • Clinical Research Site

    Gainesville, Florida · Recruiting

  • Clinical Research Site

    Jacksonville, Florida · Recruiting

  • Clinical Research Site

    Maitland, Florida · Recruiting

  • Clinical Research Site

    Orlando, Florida · Recruiting

  • Clinical Research Site

    Orlando, Florida · Recruiting

  • Clinical Research Site

    Atlanta, Georgia · Recruiting

  • Clinical Research Site

    Union City, Georgia · Recruiting

  • Clinical Research Site

    Bardstown, Kentucky · Recruiting

  • Clinical Research Site

    Owensboro, Kentucky · Recruiting

  • Clinical Research Site

    Springfield, Massachusetts · Recruiting

  • Clinical Research Site

    Worcester, Massachusetts · Recruiting

  • Clinical Research Site

    Jackson, Mississippi · Recruiting

  • Clinical Research Site

    Las Vegas, Nevada · Recruiting

  • Clinical Research Site

    Staten Island, New York · Recruiting

  • Clinical Research Site

    Portland, Oregon · Recruiting

  • Clinical Research Site

    North Charleston, South Carolina · Recruiting

  • Clinical Research Site

    Memphis, Tennessee · Recruiting

  • Clinical Research Site

    Austin, Texas · Recruiting

  • Clinical Research Site

    Friendswood, Texas · Recruiting

  • Clinical Research Site

    San Antonio, Texas · Recruiting

  • Clinical Research Site

    Provo, Utah · Recruiting

  • Clinical Research Site

    Fairfax, Virginia · Recruiting

  • Clinical Research Site

    Petersburg, Virginia · Recruiting

  • Clinical Research Site

    Everett, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.